Found: 5
Select item for more details and to access through your institution.
Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID‐19 convalescent plasma donors.
- Published in:
- Transfusion, 2021, v. 61, n. 7, p. 2099, doi. 10.1111/trf.16401
- By:
- Publication type:
- Article
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
- Published in:
- Drug Design, Development & Therapy, 2015, v. 9, p. 3435, doi. 10.2147/DDDT.S80928
- By:
- Publication type:
- Article
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
- Published in:
- Drug Design, Development & Therapy, 2015, v. 9, p. 3435, doi. 10.2147/DDDT.S80928
- By:
- Publication type:
- Article
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial.
- Published in:
- Journal of Inherited Metabolic Disease, 2019, v. 42, n. 3, p. 534, doi. 10.1002/jimd.12080
- By:
- Publication type:
- Article
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0134341
- By:
- Publication type:
- Article